替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析

周泓羽; 杜渝平; 袁喆

您当前的位置：

首页 >

文章列表页 >

替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析

论著 | 更新时间：2026-01-09

- 替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析
- Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis
- 陆军军医大学学报 2013年35卷第20期页码：2220-2225
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  中图分类号： R181.23;R512.62;R978.7
- 纸质出版：2013
- 稿件说明：
移动端阅览
周泓羽,杜渝平,袁喆.替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2013,35(20):2220-2225.

　Zhou Hongyu,Du Yuping,Yuan Zhe.Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(20):2220-2225.
周泓羽,杜渝平,袁喆.替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析[J].陆军军医大学学报(原第三军医大学学报),2013,35(20):2220-2225. DOI：

　Zhou Hongyu,Du Yuping,Yuan Zhe.Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(20):2220-2225. DOI：

摘要

目的综合评价替比夫定阻断乙型肝炎病毒母婴传播的效果。方法检索国内外有关替比夫定阻断HBV母婴传播的临床对照试验文献，通过Meta分析方法，对HBV感染孕妇的HBV DNA定量水平及婴儿HBsAg、HBV DNA血清学阳性率进行合并分析。结果替比夫定组孕妇HBV DNA水平较治疗前下降（WMD=3.62，95%CI=3.41~3.82，

0.01），且分娩前HBV DNA水平低于对照组（WMD=-3.51，95%CI=-3.79~-3.23，

0.01）。婴儿出生后24 h内，替比夫定组的HBsAg阳性率、HBV DNA阳性率分别为11.5%、3.9%，低于对照组的25.8%、17.7%（RR=0.45，95%CI=0.32~0.63，

0.01；RR=0.26，95%CI=0.15~0.44，

0.01）。婴儿6月龄，替比夫定组的HBV DNA阳性率为2.6%，低于对照组的19.2%（RR=0.15，95%CI=0.06~0.39，

0.01）。婴儿12月龄，替比夫定组的HBsAg阳性率、HBV DNA阳性率分别为3.8%、2.2%，低于对照组的21.5%、16.6%（RR=0.18，95%CI=0.09~0.39，

0.01；RR=0.15，95%CI=0.06~0.38，

0.01）。结论在孕中后期使用替比夫定进行抗病毒治疗，能够降低孕妇乙肝病毒载量，最终起到较好的乙型肝炎病毒母婴阻断效果。

Abstract

Objective To evaluate the efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus (HBV)

and to provide a basis for the prevention and control of mother-to-child transmission of HBV. Methods We retrieved the domestic and foreign literatures about controlled clinical trials of telbivudine preventing mother-to-child transmission of HBV. Meta-a

nalysis was used to analyze HBV DNA level of HBV-infected pregnant women

and HBsAg and HBV DNA seropositivity of infants. Results The HBV DNA level of pregnant women of telbivudine group was decreased after treatment (WMD=3.62

95%CI=3.41 to 3.82

0.01)

and was lower than those in control group before parturition (WMD=-3.51

95%CI=-3.79 to -3.23

0.01). Within 24 hours after infants birth

the seropositivity of HBsAg and HBV DNA of telbivudine group infants were 11.5% and 3.9% respectively

lower than those in control group

25.8% and 17.7% respectively (RR=0.45

95%CI=0.32 to 0.63

0.01; RR=0.26

95%CI=0.15 to 0.44

0.01). The HBV DNA seropositivity of 6-month infants from telbivudine group was 2.6%

lower than 19.2% for the control group (RR=0.15

95%CI=0.06 to 0.39

0.01). The seropositivity of HBsAg and HBV DNA of 12-month infants from telbivudine group were 3.8% and 2.2% respectively

lower than 21.5% and 16.6% for the control group (RR=0.18

95%CI=0.09 to 0.39

0.01; RR=0.15

95%CI=0.06 to 0.38

0.01). Conclusion Telbivudine treatment during the second and third trimester of pregnancy reduces HBV DNA level in pregnant women

and ultimately prevents mother-to-child transmission of HBV.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

益生菌辅助治疗帕金森病的Meta分析

302例HBV母婴阻断婴幼儿HBV血清标志物动态分析

猪腹部爆炸伤损害控制手术模型的建立及效果观察

HBeAg阳性感染孕妇妊娠期中晚期接受替比夫定治疗对HBsAg、HBeAg及抗-HBc胎盘透过率的影响